<p>Apellis Pharmaceuticals, Inc.（纳斯达克代码：APLS - 获取免费报告）首席会计官 James George Chopas 于 1 月 13 日（星期二）出售了 873 股该股票。股票的平均售价为 22.19 美元，总价值为 19,371.87 美元。出售完成后，首席会计官直接持有公司 52,595 股股票，价值约为 1,167,083.05 美元。这代表其持股比例减少了 1.63%。此次出售在向 SEC 的备案中披露，相关信息可通过 SEC 网站访问。</p>
<h2>Apellis Pharmaceuticals 股票上涨 1.0%</h2>
<ul>
<li>Beam Therapeutics 因基因治疗许可支付而大幅上涨</li>
</ul>
<p>在周四的午盘交易中，纳斯达克 APLS 的股票上涨了 0.20 美元，达到了 20.53 美元。该公司的交易量为 2,191,474 股，而其平均交易量为 3,495,767 股。该公司的债务与股本比率为 0.90，速动比率为 3.10，流动比率为 3.54。公司的市值为 26 亿美元，市盈率为 66.23，贝塔值为 0.31。该股票的 50 日移动平均线为 22.86 美元，200 日移动平均线为 23.41 美元。Apellis Pharmaceuticals, Inc.的 12 个月低点为 16.10 美元，12 个月高点为 31.17 美元。</p>
<p>Apellis Pharmaceuticals（纳斯达克代码：APLS - 获取免费报告）最近于 10 月 30 日（星期四）发布了季度财报。公司报告该季度每股收益为 1.67 美元，超出市场共识预期的 1.03 美元，超出幅度为 0.64 美元。该季度的收入为 4.5858 亿美元，而分析师预期为 3.6458 亿美元。Apellis Pharmaceuticals 的净利润率为 4.43%，股本回报率为 18.94%。与去年同期相比，该季度的收入增长了 133.0%。在去年同期，该公司每股收益为（0.46）美元。整体来看，股票研究分析师预计 Apellis Pharmaceuticals, Inc.在当前年度将发布-1.7 美元的每股收益。</p>
<h2>机构资金流入和流出</h2>
<ul>
<li>小型股是否预示市场下跌？</li>
</ul>
<p>一些机构投资者最近调整了对 APLS 的持股。Parallel Advisors LLC 在第二季度将其在 Apellis Pharmaceuticals 的持股增加了 80.0%。Parallel Advisors LLC 目前持有该公司 1,924 股股票，价值 33,000 美元，此前在上个季度增持了 855 股。Jones Financial Companies Lllp 在第三季度将其在 Apellis Pharmaceuticals 的持股增加了 206.8%。Jones Financial Companies Lllp 目前持有该公司 2,037 股股票，价值 46,000 美元，此前在上个季度增持了 1,373 股。Allworth Financial LP 在第三季度将其在 Apellis Pharmaceuticals 的持股增加了 64.1%。Allworth Financial LP 目前持有该公司 2,194 股股票，价值 50,000 美元，此前在上个季度增持了 857 股。Osaic Holdings Inc.在第二季度将其在 Apellis Pharmaceuticals 的持股增加了 141.2%。Osaic Holdings Inc.目前持有该公司 2,682 股股票，价值 47,000 美元，此前在上个季度增持了 1,570 股。最后，Quantbot Technologies LP 在第三季度收购了 Apellis Pharmaceuticals 的新股份，价值 64,000 美元。机构投资者持有该公司 96.29% 的股票。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位研究分析师对 APLS 股票发表了看法。花旗集团在 10 月 31 日（星期五）的研究报告中将 Apellis Pharmaceuticals 的目标价格从 52.00 美元下调至 45.00 美元，并对该股票给予 “买入” 评级。富国银行在 10 月 15 日（星期三）的研究报告中开始覆盖 Apellis Pharmaceuticals 的股票。他们给予 “增持” 评级，并设定 32.00 美元的价格目标。Needham &amp; Company LLC 在周二将 Apellis Pharmaceuticals 的目标价格从 29.00 美元下调至 28.00 美元，并对该公司给予 “买入” 评级。瑞穗证券在 11 月 3 日（星期一）的研究报告中将 Apellis Pharmaceuticals 的目标价格从 24.00 美元下调至 19.00 美元，并对该股票给予 “中性” 评级。最后，TD Cowen 在 10 月 31 日（星期五）的研究报告中将 Apellis Pharmaceuticals 的价格目标从 50.00 美元下调至 45.00 美元，并对该公司给予 “买入” 评级。共有 11 位研究分析师对该股票给予 “买入” 评级，7 位给予 “持有” 评级，2 位给予 “卖出” 评级。根据 MarketBeat，Apellis Pharmaceuticals 目前的共识评级为 “持有”，平均目标价格为 33.65 美元。</p>
<p><strong>阅读我们最新的 APLS 股票分析</strong></p>
<h2>Apellis Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Apellis Pharmaceuticals, Inc.，以纳斯达克代码 APLS 交易，是一家临床阶段的生物制药公司，专注于开发针对补体级联反应的新疗法，以治疗罕见且严重的疾病。公司的研发工作集中在调节补体蛋白，以应对一系列眼科、血液和肾脏疾病。Apellis 利用其专有的 compstatin 技术平台设计针对性抑制剂，旨在改善患者的治疗效果和生活质量。</p>
<p>该公司的主要市场产品 Syfovre（pegcetacoplan）是一种用于治疗与年龄相关的黄斑变性引起的地理萎缩的玻璃体内补体 C3 抑制剂，并正在对其他视网膜疾病进行持续研究。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Apellis Pharmaceuticals</li>
<li>Elon 将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 悄然激活</li>
<li>执行命令 14330：特朗普最大的举措</li>
<li>崩盘已经开始（大多数人尚未察觉）</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Apellis Pharmaceuticals 吗？</h2>
<p>在考虑 Apellis Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Apellis Pharmaceuticals 并不在名单上。</p>
<p>虽然 Apellis Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

APLS

<p>Apellis Pharmaceuticals 的首席会计官 James George Chopas 出售了 873 股，价格为每股 22.19 美元，总计 19,371.87 美元，减少了 1.63% 的持股，现持有 52,595 股，估值约为 117 万美元。该交易已向美国证券交易委员会（SEC）披露。该股票最近的交易价格为 20.53 美元，市值为 26 亿美元，市盈率为 66.23。分析师们的目标价格各不相同，花旗集团将其目标价从 52 美元下调至 45 美元，而富国银行则设定了 32 美元的目标价。机构投资者持有该股票的 96.29%</p>

<p>Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) CAO James George Chopas sold 873 shares of the stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $22.19, for a total value of $19,371.87. Following the completion of the sale, the chief accounting officer directly owned 52,595 shares of the company's stock, valued at approximately $1,167,083.05. This represents a 1.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals, Inc.（纳斯达克代码：APLS - 获取免费报告）首席会计官 James George Chopas 于 1 月 13 日（星期二）出售了 873 股该股票。股票的平均售价为 22.19 美元，总价值为 19,371.87 美元。出售完成后，首席会计官直接持有公司 52,595 股股票，价值约为 1,167,083.05 美元。这代表其持股比例减少了 1.63%。此次出售在向 SEC 的备案中披露，相关信息可通过 SEC 网站访问。</p>
</div><h2>Apellis Pharmaceuticals Stock Up 1.0%</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 股票上涨 1.0%</h2>
</div><ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><ul>
<li>Beam Therapeutics 因基因治疗许可支付而大幅上涨</li>
</ul>
</div><p>Shares of NASDAQ APLS traded up $0.20 during mid-day trading on Thursday, reaching $20.53. The company had a trading volume of 2,191,474 shares, compared to its average volume of 3,495,767. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54. The company has a market capitalization of $2.60 billion, a price-to-earnings ratio of 66.23 and a beta of 0.31. The stock has a fifty day moving average of $22.86 and a two-hundred day moving average of $23.41. Apellis Pharmaceuticals, Inc. has a 12-month low of $16.10 and a 12-month high of $31.17.</p>
<div class="lb-trans"><p>在周四的午盘交易中，纳斯达克 APLS 的股票上涨了 0.20 美元，达到了 20.53 美元。该公司的交易量为 2,191,474 股，而其平均交易量为 3,495,767 股。该公司的债务与股本比率为 0.90，速动比率为 3.10，流动比率为 3.54。公司的市值为 26 亿美元，市盈率为 66.23，贝塔值为 0.31。该股票的 50 日移动平均线为 22.86 美元，200 日移动平均线为 23.41 美元。Apellis Pharmaceuticals, Inc.的 12 个月低点为 16.10 美元，12 个月高点为 31.17 美元。</p>
</div><p>Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings data on Thursday, October 30th. The company reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.64. The firm had revenue of $458.58 million for the quarter, compared to analyst estimates of $364.58 million. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The company's revenue for the quarter was up 133.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.46) EPS. As a group, equities research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals（纳斯达克代码：APLS - 获取免费报告）最近于 10 月 30 日（星期四）发布了季度财报。公司报告该季度每股收益为 1.67 美元，超出市场共识预期的 1.03 美元，超出幅度为 0.64 美元。该季度的收入为 4.5858 亿美元，而分析师预期为 3.6458 亿美元。Apellis Pharmaceuticals 的净利润率为 4.43%，股本回报率为 18.94%。与去年同期相比，该季度的收入增长了 133.0%。在去年同期，该公司每股收益为（0.46）美元。整体来看，股票研究分析师预计 Apellis Pharmaceuticals, Inc.在当前年度将发布-1.7 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><ul>
<li>Are Small Caps a Harbinger of Market Declines?</li>
</ul>
<div class="lb-trans"><ul>
<li>小型股是否预示市场下跌？</li>
</ul>
</div><p>A number of institutional investors have recently modified their holdings of APLS. Parallel Advisors LLC grew its position in Apellis Pharmaceuticals by 80.0% during the 2nd quarter. Parallel Advisors LLC now owns 1,924 shares of the company's stock worth $33,000 after acquiring an additional 855 shares during the last quarter. Jones Financial Companies Lllp boosted its stake in Apellis Pharmaceuticals by 206.8% in the third quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company's stock worth $46,000 after purchasing an additional 1,373 shares in the last quarter. Allworth Financial LP grew its holdings in shares of Apellis Pharmaceuticals by 64.1% during the third quarter. Allworth Financial LP now owns 2,194 shares of the company's stock worth $50,000 after purchasing an additional 857 shares during the last quarter. Osaic Holdings Inc. grew its holdings in shares of Apellis Pharmaceuticals by 141.2% during the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company's stock worth $47,000 after purchasing an additional 1,570 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Apellis Pharmaceuticals in the third quarter valued at $64,000. Institutional investors own 96.29% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者最近调整了对 APLS 的持股。Parallel Advisors LLC 在第二季度将其在 Apellis Pharmaceuticals 的持股增加了 80.0%。Parallel Advisors LLC 目前持有该公司 1,924 股股票，价值 33,000 美元，此前在上个季度增持了 855 股。Jones Financial Companies Lllp 在第三季度将其在 Apellis Pharmaceuticals 的持股增加了 206.8%。Jones Financial Companies Lllp 目前持有该公司 2,037 股股票，价值 46,000 美元，此前在上个季度增持了 1,373 股。Allworth Financial LP 在第三季度将其在 Apellis Pharmaceuticals 的持股增加了 64.1%。Allworth Financial LP 目前持有该公司 2,194 股股票，价值 50,000 美元，此前在上个季度增持了 857 股。Osaic Holdings Inc.在第二季度将其在 Apellis Pharmaceuticals 的持股增加了 141.2%。Osaic Holdings Inc.目前持有该公司 2,682 股股票，价值 47,000 美元，此前在上个季度增持了 1,570 股。最后，Quantbot Technologies LP 在第三季度收购了 Apellis Pharmaceuticals 的新股份，价值 64,000 美元。机构投资者持有该公司 96.29% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several research analysts have weighed in on APLS shares. Citigroup dropped their target price on Apellis Pharmaceuticals from $52.00 to $45.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, October 31st. Wells Fargo &amp; Company assumed coverage on shares of Apellis Pharmaceuticals in a research report on Wednesday, October 15th. They set an &#34;overweight&#34; rating and a $32.00 price objective for the company. Needham &amp; Company LLC reduced their target price on shares of Apellis Pharmaceuticals from $29.00 to $28.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday. Mizuho lowered their price target on Apellis Pharmaceuticals from $24.00 to $19.00 and set a &#34;neutral&#34; rating on the stock in a research note on Monday, November 3rd. Finally, TD Cowen reduced their price objective on Apellis Pharmaceuticals from $50.00 to $45.00 and set a &#34;buy&#34; rating for the company in a research report on Friday, October 31st. Eleven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Apellis Pharmaceuticals currently has a consensus rating of &#34;Hold&#34; and an average target price of $33.65.</p>
<div class="lb-trans"><p>几位研究分析师对 APLS 股票发表了看法。花旗集团在 10 月 31 日（星期五）的研究报告中将 Apellis Pharmaceuticals 的目标价格从 52.00 美元下调至 45.00 美元，并对该股票给予 “买入” 评级。富国银行在 10 月 15 日（星期三）的研究报告中开始覆盖 Apellis Pharmaceuticals 的股票。他们给予 “增持” 评级，并设定 32.00 美元的价格目标。Needham &amp; Company LLC 在周二将 Apellis Pharmaceuticals 的目标价格从 29.00 美元下调至 28.00 美元，并对该公司给予 “买入” 评级。瑞穗证券在 11 月 3 日（星期一）的研究报告中将 Apellis Pharmaceuticals 的目标价格从 24.00 美元下调至 19.00 美元，并对该股票给予 “中性” 评级。最后，TD Cowen 在 10 月 31 日（星期五）的研究报告中将 Apellis Pharmaceuticals 的价格目标从 50.00 美元下调至 45.00 美元，并对该公司给予 “买入” 评级。共有 11 位研究分析师对该股票给予 “买入” 评级，7 位给予 “持有” 评级，2 位给予 “卖出” 评级。根据 MarketBeat，Apellis Pharmaceuticals 目前的共识评级为 “持有”，平均目标价格为 33.65 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on APLS</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 APLS 股票分析</strong></p>
</div><h2>Apellis Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company's research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals, Inc.，以纳斯达克代码 APLS 交易，是一家临床阶段的生物制药公司，专注于开发针对补体级联反应的新疗法，以治疗罕见且严重的疾病。公司的研发工作集中在调节补体蛋白，以应对一系列眼科、血液和肾脏疾病。Apellis 利用其专有的 compstatin 技术平台设计针对性抑制剂，旨在改善患者的治疗效果和生活质量。</p>
</div><p>The company's lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.</p>
<div class="lb-trans"><p>该公司的主要市场产品 Syfovre（pegcetacoplan）是一种用于治疗与年龄相关的黄斑变性引起的地理萎缩的玻璃体内补体 C3 抑制剂，并正在对其他视网膜疾病进行持续研究。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Apellis Pharmaceuticals</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Executive Order 14330: Trump’s Biggest Yet</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Apellis Pharmaceuticals</li>
<li>Elon 将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 悄然激活</li>
<li>执行命令 14330：特朗普最大的举措</li>
<li>崩盘已经开始（大多数人尚未察觉）</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=APLS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Apellis Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Apellis Pharmaceuticals 吗？</h2>
</div><p>Before you consider Apellis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Apellis Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apellis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Apellis Pharmaceuticals 并不在名单上。</p>
</div><p>While Apellis Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Apellis Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

内部人士出售：Apellis Pharmaceuticals（NASDAQ:APLS）的首席会计官出售了价值 19,371.87 美元的股票